Thursday, July 15, 2004
Wednesday, July 14, 2004
The Struggle for Mastery in Insulin Action:
ype 2 diabetes arises from a combination of impaired insulin action and defective pancreatic β-cell function. Classically, the two abnormalities have been viewed as distinct yet mutually detrimental processes. The combination of impaired insulin-dependent glucose metabolism in skeletal muscle and impaired β-cell function causes an increase of hepatic glucose production, leading to a constellation of tissue abnormalities that has been referred to as the diabetes "ruling triumvirate." Targeted mutagenesis in mice has led to a critical reappraisal of the integrated physiology of insulin action
ype 2 diabetes arises from a combination of impaired insulin action and defective pancreatic β-cell function. Classically, the two abnormalities have been viewed as distinct yet mutually detrimental processes. The combination of impaired insulin-dependent glucose metabolism in skeletal muscle and impaired β-cell function causes an increase of hepatic glucose production, leading to a constellation of tissue abnormalities that has been referred to as the diabetes "ruling triumvirate." Targeted mutagenesis in mice has led to a critical reappraisal of the integrated physiology of insulin action
Wednesday, July 07, 2004
Dual Blockade of Renin-Angiotensin System Renoprotective...: "Aug. 1, 2003 � Dual blockade of the renin-angiotensin system (RAS) is renoprotective in type 2 diabetes, according to the results of a double-blind, randomized trial published in the August issue of Diabetes Care. Adding an angiotensin II receptor blocker (ARB) to treatment with maximal recommended doses of an angiotensin-converting enzyme (ACE) inhibitor provided superior short-term renoprotection independent of systemic blood pressure changes."
Adding Thiazolidinedione to Metformin Plus Insulin Improves...: "July 1, 2004 � Adding thiazolidinedione to metformin (MET) plus insulin (INS) improved glycemic control and reduced INS dose without increasing weight gain, according to the results of a randomized trial published in the July issue of Diabetes Care. The editorialist suggests that treating to target is all that matters, regardless of what combination of medications is used. Cost and lifestyle should be considered in choosing optimal triple therapy."
Friday, July 02, 2004
News - Metformin Shows Promise for Diabetes Prevention, but Further Studies Needed
Metformin may help prevent type 2 diabetes in individuals at high risk of developing the disease, but new studies must evaluate its long-term safety, efficacy, cost-effectiveness, according to Donald L. Sullivan, PhD, RPh, and Aleda M. Hess, Pharm D, both of Ohio Northern University, Ada, United States.
Metformin may help prevent type 2 diabetes in individuals at high risk of developing the disease, but new studies must evaluate its long-term safety, efficacy, cost-effectiveness, according to Donald L. Sullivan, PhD, RPh, and Aleda M. Hess, Pharm D, both of Ohio Northern University, Ada, United States.
News - Rosiglitazone Could Have Antiinflammatory Effects: "Thiazolidinedione rosiglitazone, a selective agonist of peroxisome proliferator-activated receptor gamma has demonstrated antiinflammatory effects, according to a new American study.
Troglitazone, a thiazolidinedione agonist of peroxisome proliferator-activated receptor gamma (PPAR�) and a partial agonist of PPAR�, was previously shown to have a significant antiinflammatory activity in a trial of diabetic obese patients and nondiabetic obese subjects, writes P. Mohanty, MD, and colleagues, Division of Endocrinology, Diabetes and Metabolism, State University of New York, New York."
Troglitazone, a thiazolidinedione agonist of peroxisome proliferator-activated receptor gamma (PPAR�) and a partial agonist of PPAR�, was previously shown to have a significant antiinflammatory activity in a trial of diabetic obese patients and nondiabetic obese subjects, writes P. Mohanty, MD, and colleagues, Division of Endocrinology, Diabetes and Metabolism, State University of New York, New York."
Webcast/CME - Evolution of Type 2 Diabetes: The Time for Insulin is Now
This multi-media webcast reviews the goals of type 2 diabetes management, the benefits of intensive therapy, guidelines for measurement of glycaemic control, and practical strategies for helping achieve and maintain glycaemic control via intensive therapy methodologies
This multi-media webcast reviews the goals of type 2 diabetes management, the benefits of intensive therapy, guidelines for measurement of glycaemic control, and practical strategies for helping achieve and maintain glycaemic control via intensive therapy methodologies
Adding Thiazolidinedione to Metformin Plus Insulin Improves...
July 1, 2004 — Adding thiazolidinedione to metformin (MET) plus insulin (INS) improved glycemic control and reduced INS dose without increasing weight gain, according to the results of a randomized trial published in the July issue of Diabetes Care. The editorialist suggests that treating to target is all that matters, regardless of what combination of medications is used. Cost and lifestyle should be considered in choosing optimal triple therapy.
July 1, 2004 — Adding thiazolidinedione to metformin (MET) plus insulin (INS) improved glycemic control and reduced INS dose without increasing weight gain, according to the results of a randomized trial published in the July issue of Diabetes Care. The editorialist suggests that treating to target is all that matters, regardless of what combination of medications is used. Cost and lifestyle should be considered in choosing optimal triple therapy.
Subscribe to:
Posts (Atom)